Psychedelic drug abuse potential assessment for new drug applications and controlled substance scheduling: A United States perspective

Abstract

Background:

Psychedelics are an increasingly active area of research and pharmaceutical development. This includes abuse potential assessment to better understand their pharmacological mechanisms and effects and guide controlled substance regulation. Psychedelics pose challenges to abuse assessments to ensure valid, reliable, and generalizable outcomes and safe study conduct.

Findings:

Key nonclinical techniques, for example, receptor binding and functional assays in vitro, and nonclinical physical dependence determinations, are easily adaptable to psychedelics. However, the entactogens (weak reinforcers) and hallucinogens (non-reinforcers) require more flexible approaches than typically recommended by regulatory agencies. Phase 1 pharmacokinetic/pharmacodynamic safety studies and Phases 2/3 efficacy/safety trials with systematic monitoring of abuse-related adverse events are readily applicable to psychedelics. Human abuse trials require modification because supratherapeutic doses may not be safe and procedures, for example, personal monitors to manage serious adverse events, might bias outcomes.

Recommendations:

Abuse-related studies for psychedelics requiring approval by Food and Drug Administration and other agencies should take into consideration existing knowledge that will vary from extensive, for example, psilocybin, to zero for novel hallucinogens and entactogens. Many abuse assessments can be reasonably applied to animals and humans without compromising scientific integrity. Modification of existing techniques and incorporating a broader range of nonclinical tests should ensure generalizable outcomes. Human abuse studies merit reconsideration and possible modification to ensure safety and validity for psychedelic drug evaluation. Other nonclinical and clinical methods can provide evaluations of the pharmacological equivalence of test drugs to known drugs of abuse to provide context to the abuse assessment and guide drug scheduling.

Keywords

Psychedelics LSD psilocybin MDMA abuse potential assessment self-administration animal and human reinforcement drug scheduling

Get full access to this article

View all access options for this article.

References

Ator

Griffiths

(2003) Principles of drug abuse liability assessment in laboratory animals. Drug Alcohol Depend 70: S55–S72.

Bauer

Banks

Blough

, et al. (2013) Rate-dependent effects of monoamine releasers on intracranial self-stimulation in rats: Implications for abuse liability assessment. Behav Pharmacol 24(5–6): 448–458.

Baumann

Walters

Niello

, et al. (2018) Neuropharmacology of synthetic cathinones. Handb Exp Pharmacol 252: 113–142.

Belouin

Henningfield

(2018) Psychedelics: Where we are now, why we got here, what we must do. Neuropharmacology 142: 7–19.

Bonson

(2018) Regulation of human research with LSD in the United States (1949–1987). Psychopharmacology (Berl) 235: 591–604.

Born

Gauvin

Mukherjee

, et al. (2017) Preclinical assessment of the abuse potential of the orexin receptor antagonist, suvorexant. Regul Toxicol Pharmacol 86: 181–192.

Calderon

Bonson

Reissig

, et al. (2022) Considerations in assessing the abuse potential of psychedelics during drug development. Neuropharmacol. Epub ahead of print 28 November 2022. DOI: 10.1016/j.neuropharm.2022.109352.

Calderon

Giarola

Heal

(2015) Regulatory framework and guidance to the evaluation of the abuse liability of drugs in the United States and Europe. In: CG

Markgraf

Hudzik

Compton

(eds) Nonclinical Assessment of Abuse Potential for New Pharmaceuticals. Cambridge, MA: Academic Press, pp. 245–268.

Calderon

Hunt

Klein

(2018) A regulatory perspective on the evaluation of hallucinogen drugs for human use. Neuropharmacology 142: 135–142.

10.

Carbonaro

Johnson

Griffiths

(2020) Subjective features of the psilocybin experience that may account for its self-administration by humans: A double-blind comparison of psilocybin and dextromethorphan. Psychopharmacology (Berl) 237: 2293–2304.

11.

Carter

Griffiths

(2009) Principles of laboratory assessment of drug abuse liability and implications for clinical development. Drug Alcohol Depend 105: S14–S25.

12.

Coker

Yazar-Klosinski

Emerson

, et al. (2021). American College of Neuropsychopharmacology 60th Annual Meeting, 5–8 December, Puerto Rico.

13.

Corne

Pickering

(1967) A possible correlation between drug-induced hallucinations in man and a behavioural response in mice. Psychopharmacologia 11: 65–78.

14.

European Medicines Agency (2000) ICH S7A safety pharmacology studies for human pharmaceuticals. Available at https://www.ema.europa.eu/en/ich-s7a-safety-pharmacology-studies-human-pharmaceuticals (accessed 31 December 2021).

15.

European Medicines Agency (2006) Guidance of the non-clinical investigation of the dependence potential of medicinal products. Available at http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003360.pdf (accessed 31 December 2021).

16.

Fantegrossi

Murnane

Reissig

(2008) The behavioral pharmacology of hallucinogens. Biochem Pharmacol 75: 17–33.

17.

Fantegrossi

Woods

Winger

(2004). Transient reinforcing effects of phenylisopropylamine and indolealkylamine hallucinogens in rhesus monkeys. Behav Pharmacol 15(2): 149–157.

18.

Gauvin

Dalton

Harter

, et al. (2019) Relative equivalence of CNS safety (FOB) assessment outcomes in male and female Wistar-Han and Sprague-Dawley rats. J Pharmacol Toxicol Methods 95: 2–11.

19.

Gauvin

Yoder

Holdsworth

, et al. (2016) The standardized functional observational battery: Its intrinsic value remains in the instrument of measure: The rat. J Pharmacol Toxicol Methods 82: 90–108.

20.

Gauvin

Zimmermann

Kallman

(2021) Nonclinical abuse liability testing of new CNS-active drugs: Role of sex as a critical factor for drug scheduling. Drug Sci, Policy Law 7: 1–24.

21.

Griffiths

Bigelow

Ator

(2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70: S41–S54.

22.

Griffiths

Bigelow

Henningfield

(1980) Similarities in animal and human drug-taking behavior. In: NK

Mello

(ed.) Advances in Substance Abuse. Greenwich, CT: JAI Press, Inc, pp. 1–90.

23.

Griffiths

Richards

Mccann

, et al. (2006) Psilocybin can occasion mystical-type experiences having substantial and sustained personal meaning and spiritual significance. Psychopharmacology (Berl) 187: 268–283.

24.

Griffiths

Richards

Johnson

, et al. (2008) Mystical-type experiences occasioned by psilocybin mediate the attribution of personal meaning and spiritual significance 14 months later. J Psychopharmacol 22: 621–632.

25.

Halberstadt

(2015) Recent advances in the neuropsychopharmacology of serotonergic hallucinogens. Behav Brain Res 277: 99–120.

26.

Halberstadt

Chatha

Klein

, et al. (2020) Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Neuropharmacology 167: 107933.

27.

Heal

Gosden

Smith

(2018a) Evaluating the abuse potential of psychedelic drugs as part of the safety pharmacology assessment for medical use in humans. Neuropharmacology 142: 89–115.

28.

Heal

Kulkarni

Pinder

, et al. (2018c) Dasotraline is a monoamine reuptake inhibitor not a releasing agent as revealed by tetrodotoxin (TTX) sensitivity in microdialysis in the nucleus accumbens of freely-moving rats. Presented at the 80th annual meeting of college on problems of drug dependence, Washington, DC June 9–14. Available at https://d2p55c5k0gw6a2.cloudfront.net/wp-content/uploads/2018/10/abstracts_2018_for_app_update_101918.pdf#page=444

29.

Heal

Luscombe

Martin

(1992) Pharmacological identification of 5-HT receptor subtypes using behavioural models. In: CA

Marsden

Heal

(eds) Central Serotonin Receptors and Psychotropic Drugs. Oxford: Blackwell Scientific Publications, pp.56–99.

30.

Heal

Smith

Gosden

, et al. (2018b) An investigation of the discriminative stimulus and reinforcing effects of cannabidiol in rats. Presented at The society for neurosciences neuroscience meeting, Washington, DC November 3–7. Available at https://www.abstractsonline.com/pp8/#!/4649/presentation/25834

31.

Henningfield

Coe

Griffiths

, et al. (2022) Psychedelic drug abuse potential assessment research for new drug applications and Controlled Substances Act scheduling. Neuropharmacol. Epub ahead of print 1 November 2022. DOI: 10.1016/j.neuropharm.2022.109220.

32.

Hofmann

. (2013) LSD: My Problem Child and Insights/Outlooks. New York, NY, US: Oxford University Press.

33.

International Narcotics Control Board (1994) Report of the International Narcotics Control Board for 1994. Vienna: International Narcotics Control Board.

34.

Jackson

Authier

Brohmann

, et al. (2019) Neurofunctional test batteries in safety pharmacology-Current and emerging considerations for the drug development process. J Pharmacol Toxicol Methods 100: 106602.

35.

Johnson

Griffiths

Hendricks

, et al. (2018) The abuse potential of medical psilocybin according to the 8 factors of the controlled substances act. Neuropharmacology 142: 143–166.

36.

Johnson

Richards

Griffiths

(2008) Human hallucinogen research: Guidelines for safety. J Psychopharmacol 22: 603–620.

37.

National Academies of Sciences (2017) The health effects of cannabis and cannabinoids: The current state of evidence and recommendations for research. https://nap.nationalacademies.org/catalog/24625/the-health-effects-of-cannabis-and-cannabinoids-the-current-state (accessed December 2021).

38.

National Institute on Drug Abuse (2021) Hallucinogens drug facts. Available at: https://nida.nih.gov/publications/drugfacts/hallucinogens (accessed 31 December 2021).

39.

Negus

Miller

(2014) Intracranial self-stimulation to evaluate abuse potential of drugs. Pharmacol Rev 66: 869–917.

40.

Nichols

(2004). Hallucinogens. Pharmacol Ther 101(2): 131–181.

41.

O’brien

(2015) Drug addiction. In: LL

Brunton

Chabner

Knollmann

(eds) Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 12e, Chapter 24, New York, NY: McGraw-Hill Education.

42.

Pasternak

Pan

(2013) Mu opioids and their receptors: evolution of a concept. Pharmacol Rev 65: 1257–1317.

43.

Sakloth

Leggett

Moerke

, et al. (2019) Effects of acute and repeated treatment with serotonin 5-HT2A receptor agonist hallucinogens on intracranial self-stimulation in rats. Exp Clin Psychopharmacol 27: 215–226.

44.

Schoedel

Sun

Sellers

, et al. (2016) Assessment of the abuse potential of the orexin receptor antagonist, suvorexant, compared with zolpidem in a randomized crossover study. J Clin Psychopharmacol 36: 314–323.

45.

Sellers

Leiderman

(2018) Psychedelic drugs as therapeutics: No illusions about the challenges. Clin Pharmacol Ther 103: 561–564.

46.

Sellers

Romach

Leiderman

(2018) Studies with psychedelic drugs in human volunteers. Neuropharmacology 142: 116–134.

47.

Smith

Burnett

Hallam

, et al. (2018) Which drug is the most reinforcing? Comparison of heroin, cocaine, MDMA, and nicotine by intravenous self-administration. British Pharmacol Soc Abstract 176: 3065–3066. Available at https://bpspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/bph.14681

48.

Smith

Dean

Todtenkopf

, et al. (2019) Investigation of the reinforcing potential of samidorphan and naltrexone by fixed and progressive ratio intravenous self-administration testing in heroin-maintained rats. J Psychopharmacol 33: 383–391.

49.

Spillane

McAllister

(2003) Keeping the lid on: A century of drug regulation and control. Drug Alcohol Depend 70(3 Suppl): S5–12.

50.

Synan

Bowen

Heal

, et al. (2018) Preclinical abuse liability assessment of SEP-363856, a compound with a non-D2 receptor mechanism of action. Poster presented at the 59th annual American College of Neuropsychopharmacology (ACNP) virtual meeting December 6–9.

51.

U.S. Food and Drug Administration (2017) Assessment of abuse potential of drugs: Guidance for industry. US Department of Health and Human Services. Available at https://www.fda.gov/media/116739/download (accessed 31 December 2021).

52.

U.S. Food and Drug Administration (2020) CDER breakthrough therapy designation approvals. Corrected data for December 31, 2020. Available at: https://www.fda.gov/media/95302/download (accessed 31 December 2020).

53.

Westerink

BHC

Tuntler

Damsma

, et al. (1987) The use of tetrodotoxin for the characterization of drug-enhanced dopamine release in conscious rats studied by brain dialysis. Naunyn-Schmiedeberg’s Arch Pharmacol 336: 502–507.

54.

Winstock

Timmerman

Davies

, et al. (2021) Global Drug Survey (GDS) 2020 psychedlics key findings report. Available at: https://www.globaldrugsurvey.com/gds-2020-psychedelics-report/ (accessed December 2021).

55.

Yakowicz

(2021) The future of psychedelic medicine might skip the trip. Forbes. Available at: https://www.forbes.com/sites/willyakowicz/2021/06/23/the-future-of-psychedelic-medicine-might-skip-the-trip-rick-doblin-bryan-roth-mindmed-darpa-maps/?sh=61ce2828244f (accessed December 2021).